A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism

Inclusion Criteria * Participants that are currently or previously enrolled in the core study (AAAE0544 \[NCT01199614\]) and have maintained uninterrupted therapy with recombinant human parathyroid hormone (rhPTH(1-84)) (transient interruptions of up to 1 month continuously off treatment may be allowed). * Signed and dated informed consent form (ICF). * Adult men and women 18 to 85 years of age. * History of hypoparathyroidism for at least 12 months prior to rhPTH(1-84) treatment, defined by the requirement for supplemental calcium and/or active vitamin D to maintain serum calcium along with an undetectable or insufficient Parathyroid hormone (PTH) concentration. * Able to perform daily subcutaneous (SC) self-injections of study medication (or have designee perform injection). * Willingness and ability to understand and comply with the protocol. Women must agree to pregnancy testing and acceptable methods of contraception, as detailed in the protocol. Exclusion Criteria * The participant is treated or has been treated with any investigational drug, aside from rhPTH(1-84), within 30 days of consent. * As assessed by the investigator, the participant has any safety or medical issues that contraindicate participation in the study. * The participant and/or the participant's parent(s) or legally-authorized representative(s) are unable to understand the nature, scope, and possible consequences of the study. * The participant is unable to comply with the protocol, example, uncoop…